Nursing Pharmacology Fundamentals | Pharmacokinetics &
Pharmacodynamics Pass Pack | MCQ Practice & Detailed
Rationales
Module 1: Pharmacokinetics, Pharmacodynamics, Safety, and
Prescriptive Law
Question 1 — First-Pass Metabolism and Route of Administration
A 58-year-old patient with chronic angina is prescribed a medication that undergoes extensive
hepatic first-pass metabolism. The patient reports that the medication has produced little
symptomatic benefit when taken orally despite adherence. The prescriber wants to achieve a
more predictable systemic concentration without substantially increasing the dose.
Which pharmacokinetic principle best explains why an alternative route may improve systemic
drug exposure?
A. The alternative route increases renal tubular secretion of the active drug.
B. Bypassing the gastrointestinal tract can reduce hepatic first-pass metabolism and increase
bioavailability.
C. Administration through another route increases plasma protein binding and therefore
prolongs absorption.
D. Bypassing the gastrointestinal tract converts the medication into a more potent receptor
agonist.
Answer: B
Clinical Rationale
,B is correct. Bioavailability is the fraction of an administered dose that reaches systemic
circulation unchanged. Drugs administered orally may be absorbed through the gastrointestinal
tract and then transported through the portal circulation to the liver before reaching systemic
circulation. Extensive first-pass hepatic metabolism can substantially reduce the amount of
active drug available systemically. Routes such as sublingual, transdermal, intravenous, or
certain parenteral routes can circumvent or reduce first-pass metabolism.
A is incorrect. Renal tubular secretion influences elimination rather than explaining increased
systemic availability from bypassing hepatic first-pass metabolism.
C is incorrect. Protein binding primarily affects distribution and the free fraction of drug.
Increasing protein binding does not inherently improve gastrointestinal absorption or bypass
hepatic metabolism.
D is incorrect. Route of administration does not fundamentally change receptor pharmacology.
A drug's intrinsic activity at its target is generally unchanged by whether it is administered orally
or parenterally.
Advanced point: In clinical prescribing, increasing the dose to overcome extensive first-pass
metabolism may increase interpatient variability and toxicity. Altering the route can sometimes
provide a more predictable pharmacokinetic profile.
Question 2 — Passive Diffusion
A 42-year-old patient takes an orally administered medication that is highly lipid soluble and
largely unionized at physiologic ph. The drug rapidly crosses gastrointestinal epithelial
membranes without requiring a membrane transporter.
Which absorption mechanism is most likely responsible?
,A. Facilitated diffusion
B. Active transport
C. Passive lipid diffusion
D. Pinocytosis
Answer: C
Clinical Rationale
C is correct. Most drugs cross biologic membranes primarily through passive lipid diffusion.
Lipid-soluble, nonionized molecules move down their concentration gradient through the
phospholipid bilayer. No energy expenditure or specialized transporter is required.
A is incorrect. Facilitated diffusion uses a membrane carrier but does not require ATP. It is less
characteristic of a highly lipid-soluble drug readily crossing the membrane.
B is incorrect. Active transport requires a carrier and energy-dependent processes and can
move substances against a concentration gradient.
D is incorrect. Pinocytosis involves cellular uptake of fluid and larger molecules and is not the
predominant mechanism for absorption of most conventional small-molecule medications.
Clinical implication: Changes in gastric pH, ionization, intestinal motility, membrane
permeability, and surface area can substantially alter oral absorption.
Question 3 — Protein Binding
A 74-year-old patient with hypoalbuminemia begins therapy with a medication that is normally
98% albumin bound. Shortly after initiation, the patient develops dizziness and excessive
sedation despite receiving the standard dose.
Which pharmacokinetic change is most likely contributing to the adverse effects?
, A. Decreased free-drug concentration caused by reduced albumin
B. Increased free-drug concentration caused by reduced protein binding
C. Increased renal filtration caused by greater protein binding
D. Reduced hepatic access to the unbound fraction
Answer: B
Clinical Rationale
B is correct. Only the unbound/free fraction of most drugs can readily cross membranes,
interact with receptors, undergo glomerular filtration, and undergo many forms of hepatic
metabolism. Hypoalbuminemia can reduce binding sites, increasing the free fraction of a highly
protein-bound medication. This may intensify pharmacologic effects and toxicity.
A is incorrect. Reduced albumin generally increases, rather than decreases, the unbound
fraction.
C is incorrect. Increased protein binding would generally reduce glomerular filtration of the
drug because albumin-bound molecules are poorly filtered.
D is incorrect. Reduced protein binding generally increases hepatic access to free drug rather
than restricting it.
Clinical implication: Protein-binding changes are particularly important with drugs possessing a
narrow therapeutic index. A change in total serum concentration may be misleading when the
free fraction changes substantially.
Question 4 — Drug Displacement
Pharmacodynamics Pass Pack | MCQ Practice & Detailed
Rationales
Module 1: Pharmacokinetics, Pharmacodynamics, Safety, and
Prescriptive Law
Question 1 — First-Pass Metabolism and Route of Administration
A 58-year-old patient with chronic angina is prescribed a medication that undergoes extensive
hepatic first-pass metabolism. The patient reports that the medication has produced little
symptomatic benefit when taken orally despite adherence. The prescriber wants to achieve a
more predictable systemic concentration without substantially increasing the dose.
Which pharmacokinetic principle best explains why an alternative route may improve systemic
drug exposure?
A. The alternative route increases renal tubular secretion of the active drug.
B. Bypassing the gastrointestinal tract can reduce hepatic first-pass metabolism and increase
bioavailability.
C. Administration through another route increases plasma protein binding and therefore
prolongs absorption.
D. Bypassing the gastrointestinal tract converts the medication into a more potent receptor
agonist.
Answer: B
Clinical Rationale
,B is correct. Bioavailability is the fraction of an administered dose that reaches systemic
circulation unchanged. Drugs administered orally may be absorbed through the gastrointestinal
tract and then transported through the portal circulation to the liver before reaching systemic
circulation. Extensive first-pass hepatic metabolism can substantially reduce the amount of
active drug available systemically. Routes such as sublingual, transdermal, intravenous, or
certain parenteral routes can circumvent or reduce first-pass metabolism.
A is incorrect. Renal tubular secretion influences elimination rather than explaining increased
systemic availability from bypassing hepatic first-pass metabolism.
C is incorrect. Protein binding primarily affects distribution and the free fraction of drug.
Increasing protein binding does not inherently improve gastrointestinal absorption or bypass
hepatic metabolism.
D is incorrect. Route of administration does not fundamentally change receptor pharmacology.
A drug's intrinsic activity at its target is generally unchanged by whether it is administered orally
or parenterally.
Advanced point: In clinical prescribing, increasing the dose to overcome extensive first-pass
metabolism may increase interpatient variability and toxicity. Altering the route can sometimes
provide a more predictable pharmacokinetic profile.
Question 2 — Passive Diffusion
A 42-year-old patient takes an orally administered medication that is highly lipid soluble and
largely unionized at physiologic ph. The drug rapidly crosses gastrointestinal epithelial
membranes without requiring a membrane transporter.
Which absorption mechanism is most likely responsible?
,A. Facilitated diffusion
B. Active transport
C. Passive lipid diffusion
D. Pinocytosis
Answer: C
Clinical Rationale
C is correct. Most drugs cross biologic membranes primarily through passive lipid diffusion.
Lipid-soluble, nonionized molecules move down their concentration gradient through the
phospholipid bilayer. No energy expenditure or specialized transporter is required.
A is incorrect. Facilitated diffusion uses a membrane carrier but does not require ATP. It is less
characteristic of a highly lipid-soluble drug readily crossing the membrane.
B is incorrect. Active transport requires a carrier and energy-dependent processes and can
move substances against a concentration gradient.
D is incorrect. Pinocytosis involves cellular uptake of fluid and larger molecules and is not the
predominant mechanism for absorption of most conventional small-molecule medications.
Clinical implication: Changes in gastric pH, ionization, intestinal motility, membrane
permeability, and surface area can substantially alter oral absorption.
Question 3 — Protein Binding
A 74-year-old patient with hypoalbuminemia begins therapy with a medication that is normally
98% albumin bound. Shortly after initiation, the patient develops dizziness and excessive
sedation despite receiving the standard dose.
Which pharmacokinetic change is most likely contributing to the adverse effects?
, A. Decreased free-drug concentration caused by reduced albumin
B. Increased free-drug concentration caused by reduced protein binding
C. Increased renal filtration caused by greater protein binding
D. Reduced hepatic access to the unbound fraction
Answer: B
Clinical Rationale
B is correct. Only the unbound/free fraction of most drugs can readily cross membranes,
interact with receptors, undergo glomerular filtration, and undergo many forms of hepatic
metabolism. Hypoalbuminemia can reduce binding sites, increasing the free fraction of a highly
protein-bound medication. This may intensify pharmacologic effects and toxicity.
A is incorrect. Reduced albumin generally increases, rather than decreases, the unbound
fraction.
C is incorrect. Increased protein binding would generally reduce glomerular filtration of the
drug because albumin-bound molecules are poorly filtered.
D is incorrect. Reduced protein binding generally increases hepatic access to free drug rather
than restricting it.
Clinical implication: Protein-binding changes are particularly important with drugs possessing a
narrow therapeutic index. A change in total serum concentration may be misleading when the
free fraction changes substantially.
Question 4 — Drug Displacement
